OxyBridge™ for Hemorrhagic Shock
Treatment of severe blood loss in trauma
Pre-clinicalActive
Key Facts
About Virtech Bio
VirTech Bio is a private, pre-clinical biotech company developing OxyBridge™, a novel hemoglobin-based oxygen carrier (HBOC) designed to address critical unmet needs in trauma care and organ transplantation. The company's strategy involves pursuing an initial regulatory pathway through an ex vivo organ perfusion device application, anticipated for market entry in 2025, followed by the more challenging in vivo indication for hemorrhagic shock. With over $13.7 million in non-dilutive funding from U.S. DoD agencies and a management team with deep military medical and HBOC expertise, VirTech is positioning itself as a leader in next-generation oxygen therapeutic solutions.
View full company profile